Member Info for Michael2021

Until the next RNS, hopefully it will be positive, the SP gently, quietly will shift south... It doesn't matter what we think or say, the experts /market knows better, no wonder the SP is struggling to stay above 5p.

Until the next RNS, hopefully it will be positive, the SP gently, quietly will shift south... It doesn't matter what we think or say, the experts /market knows better, no wonder the SP is struggling to stay above 5p.

Before 4 o'clock. No worries.

This is not advice, just how I feel. The SP didn't move yesterday after the interview was posted on YouTube. Investors will wait for the big news, Deals with partners, Phase 3 trial...

... Deals are made Or They have no money and closing down. Nothing left here to hope.

.. So I'm happy how the company is moving forward. For those that think the SP will drop soon to 12p, please make sure you take your medication first.

We should expect an RNS within 2 weeks and this will fly off.

.. I can retire at the age of 55, but it goes to 150p, then I can retire comfortably at the age of 53. That would be absolutely brilliant.

Good luck today to all the genuine shareholders.

Bonjour

.. hopefully within a couple of weeks.

Shut you pie hole Rookie, you are paid by IMM. This is a jump the ship moment. This RNS is a warning to the shareholders who'd like to exit with some peanuts, otherwise if you wait for September you get nothing, nothing.

This RNS confirms that Tim & IMM is a con, 100% con. But you can't do nothing about it.

WE RAN OUT OF MONEY, delist and someone will buy the company for peanuts. Shareholders can do absolutely nothing about it. This RNS is a pre warning. This seems like a Titanic moment.

This is heading to 1p now

My average at the moment is about 8p.

Good luck to all genuine shareholders.

This RNS is mainly to let us know that they're running out of money soon. This doesn't look good to me.

... I don't think we will ever see 10p again.

Good luck to all the shareholders. My average is 8p, happy days.

More likely Year Of Bankruptcy

* ImmuPharma: Lupuzor (IPP-201101) is a potential treatment that has completed a Phase III trial and is embarking on a further Phase III trial with Avion Pharmaceuticals. It has received "Gold Standard" approval from the US FDA for its Phase III program with a Special Protocol Assessment (SPA) and fast track designation.

There are already 3 approved drugs for Lupus treatment, as far as l understand, or am I missing something?

It's challenging to definitively name one company nearest to achieving a "Lupus immune system drug" because drug development is a complex and ongoing process, and "nearest" can mean different things (e.g., closest to approval, most impactful in trials). However, I can highlight companies with drugs in late-stage clinical trials (Phase III) or recently approved, as these are generally considered closest to market.

Here are some key players and their promising candidates:

Recently Approved/Established Drugs:

* GSK: Their drug Benlysta (belimumab) was the first biologic approved for Systemic Lupus Erythematosus (SLE) in over five decades and also approved for lupus nephritis (LN).

* AstraZeneca: Their drug Saphnelo (anifrolumab) was approved for SLE and represents another significant advancement in targeting immune pathways.

* Aurinia Pharmaceuticals: Their drug Lupkynis (voclosporin) was approved as the first oral treatment specifically for adults with active lupus nephritis (LN).

Drugs in Late-Stage (Phase III) Development:

Several companies have drugs in Phase III trials, indicating they are closer to potential approval:

* ImmuPharma: Lupuzor (IPP-201101) is a potential treatment that has completed a Phase III trial and is embarking on a further Phase III trial with Avion Pharmaceuticals. It has received "Gold Standard" approval from the US FDA for its Phase III program with a Special Protocol Assessment (SPA) and fast track designation.

* Roche/Genentech: Obinutuzumab (Gazyva) has shown positive topline results in a Phase III study for lupus nephritis.

* Biogen: They have Litifilimab (BIIB059) and Dapirolizumab pegol in Phase III trials for lupus.

* Novartis: Ianalumab is in Phase III development.

* UCB/Biogen: Dapirolizumab pegol has reported successful results from a Phase III clinical trial (PHOENYCS GO study) for moderate-to-severe SLE.

* Idorsia Pharmaceuticals/Viatris: Cenerimod is a Phase III candidate.

* AbbVie: Upadacitinib (RINVOQ) and the combination ABBV-509 are in late-stage development for lupus.

* Bristol-Myers Squibb: Deucravacitinib (Sotyktu) targets TYK2 to block key signaling pathways involved in lupus.

* Vera Therapeutics: Atacicept is in Phase III development.

It's important to note that even with positive Phase III results, regulatory approval is not guaranteed, and the timeline for a new drug reaching the market can still vary. The field of lupus drug development is very active, with many companies working on innovative treatments targeting various aspects of the immune system involved in the disease.

Several pharmaceutical companies are making significant strides in developing immune system drugs, particularly in the field of immuno-oncology. Here are some notable ones:

## Leading Companies in Immuno-Oncology

- *Gritstone Bio*: Developing neoantigen-based cancer vaccines using AI-powered genomic sequencing to predict unique tumor mutations and train the immune system to recognize and destroy cancer cells.

- *Bristol Myers Squibb*: Focuses on developing innovative immunotherapies that activate the immune system to fight cancer, with checkpoint inhibitors transforming the treatment landscape for various types of cancer.

- *Moderna*: Harnesses mRNA technology for cancer immunotherapy, developing personalized cancer vaccines that target tumor-specific antigens.

- *Vir Biotechnology*: Leveraging next-generation antibody platforms and protease-releasable masking technology to develop medicines for infectious diseases and cancer.

- *Dragonfly Therapeutics*: Developing natural killer (NK) cell-based immunotherapies with its TriNKET platform, enhancing the immune system's ability to identify and destroy solid tumors and hematologic malignancies.

## Other Notable Companies

- *Iovance Biotherapeutics*: Developing tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, with its lead therapy, Lifileucel, in late-stage clinical trials.

- *Verastem Oncology*: Focuses on targeted therapies for hematologic malignancies and solid tumors, with its lead drug, COPIKTRA, being an FDA-approved PI3K inhibitor.

- *Evaxion Biotech*: Developing AI-powered immunotherapies for cancer treatment, with its lead cancer vaccine candidate showing promising results in clinical trials ¹ ².

These companies are pushing the boundaries of cancer treatment and immunotherapy, with some nearing FDA approval and commercialization.

.. that are working on developing an immune system drug. One of them is Pfizer . Immupharma didn't even shower up o. Google -AI search. This stock is roast, I think.